Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sarcoma 27Breast Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Large B-Cell, Diffuse 19Ovarian Neoplasms 14Neoplasms 14Lymphoma 12Burkitt Lymphoma 11Neoplasm Metastasis 10Recurrence 9Lymphoma, Non-Hodgkin 9Triple Negative Breast Neoplasms 8Neuroblastoma 7Fallopian Tube Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia 5Hodgkin Disease 5Unspecified Adult Solid Tumor, Protocol Specific 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma, T-Cell 4Lung Neoplasms 4Liposarcoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4

Interventions

Norepinephrine 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Calcitriol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Alopecia × Doxorubicin × Clear all
NCT05622058 2023-02-27

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Aileron Therapeutics, Inc.

Phase 1 Terminated
6 enrolled
Breast

Alopecia, Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡